Table 2.
Netleague laboratory-confirmed influenza: adults and elderly.
| placebo | 0.4 (0.34, 0.46) | 0.33 (0.21, 0.55) | 0.4 (0.04, 3.89) | 0.37 (0.22, 0.64) | 0.39 (0.23, 0.61) | 0.56 (0.36, 0.83) | 0.47 (0.29, 0.7) | 0.56 (0.41, 0.74) |
|---|---|---|---|---|---|---|---|---|
| 2.51 (2.18, 2.95) | 3-IIV | 0.83 (0.53, 1.37) | 1 (0.11, 9.75) | 0.94 (0.57, 1.59) | 0.97 (0.59, 1.54) | 1.41 (0.9, 2.15) | 1.18 (0.73, 1.81) | 1.41 (1.04, 1.88) |
| 3.01 (1.82, 4.86) | 1.2 (0.73, 1.88) | 3-IIV HD | 1.19 (0.12, 12.08) | 1.13 (0.57, 2.18) | 1.16 (0.57, 2.19) | 1.68 (0.87, 3.07) | 1.41 (0.71, 2.56) | 1.68 (0.94, 2.85) |
| 2.53 (0.26, 24.11) | 1 (0.1, 9.52) | 0.84 (0.08, 8.49) | 3-IIV ID | 0.95 (0.09, 9.45) | 0.97 (0.1, 9.55) | 1.41 (0.14, 13.77) | 1.17 (0.12, 11.47) | 1.41 (0.14, 13.68) |
| 2.67 (1.57, 4.5) | 1.06 (0.63, 1.74) | 0.89 (0.46, 1.75) | 1.06 (0.11, 10.86) | 3-IIV MF59/AS03-adj | 1.03 (0.49, 2.01) | 1.49 (0.76, 2.8) | 1.25 (0.62, 2.33) | 1.5 (0.82, 2.63) |
| 2.59 (1.65, 4.29) | 1.03 (0.65, 1.7) | 0.86 (0.46, 1.76) | 1.03 (0.1, 10.51) | 0.97 (0.5, 2.02) | 3-RIV | 1.44 (0.79, 2.74) | 1.21 (0.64, 2.29) | 1.45 (0.86, 2.54) |
| 1.79 (1.21, 2.76) | 0.71 (0.47, 1.11) | 0.59 (0.33, 1.15) | 0.71 (0.07, 7.15) | 0.67 (0.36, 1.32) | 0.69 (0.37, 1.27) | 4-IIV | 0.84 (0.56, 1.21) | 1 (0.61, 1.66) |
| 2.13 (1.42, 3.44) | 0.85 (0.55, 1.38) | 0.71 (0.39, 1.4) | 0.85 (0.09, 8.65) | 0.8 (0.43, 1.61) | 0.83 (0.44, 1.55) | 1.2 (0.83, 1.78) | 4-RIV | 1.2 (0.72, 2.05) |
| 1.79 (1.35, 2.43) | 0.71 (0.53, 0.96) | 0.59 (0.35, 1.06) | 0.71 (0.07, 7.02) | 0.67 (0.38, 1.23) | 0.69 (0.39, 1.17) | 1 (0.6, 1.64) | 0.84 (0.49, 1.38) | 3-LAIV |
The estimate is located at the intersection of the column-defining vaccine and the row-defining vaccine. Data are RRs (95% CrI). Significant results are in bold.
In the upper triangle, comparison of treatments should be read from right to left. An RR below 1 favors the medication on the bottom right vs. the medication on the top left in the diagonal. E.g., RR 0.40 (95% CrI 0.34–0.46) indicates a significant reduction in the incidence of laboratory-confirmed influenza for the trivalent inactivated vaccine (3-IIV) compared with placebo or no vaccination.
In the bottom triangle, comparison of treatments should be read from left to right. An RR below 1 favors the medication on the top left vs. the medication on the bottom right in the diagonal. E.g., RR 0.84 (95% CrI 0.08–8.49) indicates a non-significant reduction in the incidence of laboratory-confirmed influenza for the trivalent inactivated high-dose vaccine (3-IIV-HD) compared with the trivalent inactivated intradermal vaccine (3-IIV ID).
Abbreviations: Placebo: placebo or no vaccination; 3-IIV: trivalent inactivated intramuscular; 3-IIV HD: trivalent inactivated high-dose intramuscular; 3-IIV ID: trivalent inactivated intradermal; 3-IIV MF59/AS03-adj: trivalent inactivated adjuvanted with MF59/AS03 intramuscular; 3-RIV: trivalent recombinant intramuscular; 4-IIV: quadrivalent inactivated intramuscular; 4-RIV: quadrivalent recombinant intramuscular; 3-LAIV: trivalent live-attenuated intranasal.